Abbvie Inc
NYSE:ABBV
Abbvie Inc
Pre-Tax Income
Abbvie Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$3.7B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$690m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-26%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.6B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-2%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Pre-Tax Income
-$377.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
16%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$248.5m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$4.8B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
|
Abbvie Inc
Glance View
AbbVie Inc., a leader in the pharmaceutical industry, emerged from its parent company Abbott Laboratories in 2013, with a mission centered around addressing some of the world’s most complex and serious diseases. At its core, AbbVie is a research-driven entity that leverages scientific innovation to develop advanced therapies. With a robust pipeline, the company focuses on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, and women's health. It has developed a diversified portfolio designed to tackle challenging health issues. The company devotes significant resources to research and development, fostering a culture that celebrates scientific discovery as a pathway to improving patient lives worldwide. Revenue generation for AbbVie is deeply intertwined with its treatment offerings, particularly its lineup of blockbuster drugs. The flagship product, Humira, an anti-inflammatory medication, has consistently stood as one of the top-selling drugs globally. Despite facing patent expirations for Humira, AbbVie has strategically navigated this challenge through its robust product pipeline, which includes promising medicines like Skyrizi and Rinvoq in immunology. The company also expanded its revenue potential significantly with the acquisition of Allergan in 2020, adding Botox and other products in aesthetics and eye care to its portfolio. The calculated diversification of revenue streams ensures AbbVie maintains a competitive edge, securing its position as a formidable player in the pharmaceutical industry.
See Also
What is Abbvie Inc's Pre-Tax Income?
Pre-Tax Income
3.7B
USD
Based on the financial report for Dec 31, 2024, Abbvie Inc's Pre-Tax Income amounts to 3.7B USD.
What is Abbvie Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
5%
Over the last year, the Pre-Tax Income growth was -41%. The average annual Pre-Tax Income growth rates for Abbvie Inc have been -34% over the past three years , -15% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet